Fear of COVID-19 among employees of large companies and vaccination against COVID-19 - a cross-sectional study (Silesia, Poland)
DOI:
https://doi.org/10.12775/JEHS.2022.12.09.080Keywords
COVID-19, SARS-CoV-2, immunization, prevention, fear of infectionAbstract
Introduction and Objective. The COVID-19 pandemic has significantly affected the functioning of the entire globe. By the end of December 2020, the disease had been diagnosed in more than 82 million people worldwide, and nearly 2 million people had died. The main preventive measure was to develop an effective vaccine as soon as possible, which Pfizer/BioNTech, Moderna, AstraZeneca and Gamaleya Center managed to do in late 2020. The first vaccines arrived in Poland after the end of December 2020, but their appearance was not without controversy. The aim of this study was to compare respondents' opinions on COVID-19 vaccination with the results of the assessment of fear of infection. Material and methods. The opinions of 300 employees of large companies on COVID-19 vaccination and fear of SARS-CoV-2 (FCV-19S) infection according to Ahorsu were checked. Results. It was shown that 54% of the respondents express a willingness to vaccinate whenever possible, while 42% are not interested in vaccinating. In favor of the willingness to vaccinate is the option to return to the standard of living before the COVID-19 pandemic - 72%, and the desire to protect those around them from possible infection - 46%. Among opponents of vaccination, the predominant opinion is that the vaccine has not undergone enough testing and is not safe for health - 68%. Discussion. COVID-19 vaccination is one of the major medical successes of recent years and a safe way to prevent SARS-CoV-2 infection. It is worrying that those who opt out of vaccination indicate that they do not have enough information about vaccination (44%), and this is an issue that needs to be changed quickly. Conclusions. Those who express a willingness to vaccinate are more likely to have a higher level of fear of SARS-CoV-2 infection than those who have not expressed a willingness to vaccinate. Nearly half of non-vaccinators indicate that there is too little information about vaccination.
References
Drop B, Janiszewska M, Drop K. COVID-19 - as a global public health problem. Pol J Public Health. 2019;129(4): 118-122.
World Health Organization. Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed October 23, 2020).
Service of the Republic of Poland, Ministry of Health. Coronavirus: information and recommendations. https://www.gov.pl/web/koronawirus/wykaz-zarazen-koronawirusem-sars-cov-2 (accessed 07.01.2022).
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62 https://doi.org/10.1016/S0140- 6736(20)30566-3.
Malecki D, Grabowski M. COVID-19 in elderly patients. Impact of infection on the cardiovascular system. Gerontologia Polska. 2020; 28:52-55.
Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID 19 based on an analysis of data of 150 pa-tients from Wuhan, China. Intensive Care Med. 2020;46(6):1294-1297. https://doi.org/10.1007/s00134-020-05991-x.
Wu Z, McGoonan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China. Summary of a Report of 72,314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648.
Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus dis-ease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924.
Coelho CM, Suttiwan P, Arato N, et all. On the Nature of Fear and Anxiety Triggered by COVID-19. front. Psychol. 2020. https://doi.org/10.3389/fpsyg.2020.581314.
Republic Service. Vaccination against COVID-19 https://www.gov.pl/web/szczepimysie (accessed December 28, 2020).
Pfizer https://www.pfizer.com (accessed 10.01.2021).
Moderna https://www.modernatx.com (accessed 10.01.2021).
AstraZeneca https://www.astrazeneca.com (accessed 10.01.2021).
Sputnik V https://sputnikvaccine.com/ (accessed 10.01.2021).
Service of the Republic of Poland, Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. COVID-19 Vaccines http://www.urpl.gov.pl/sites/default/files/zalaczniki/Szczepionka%20przeciwko%20COVID-19%20kluczowe%20fakty.pdf (accessed November 30, 2020).
MedExpress. Only 17% of Poles intend to get vaccinated as soon as possible https://www.medexpress.pl/tylko-17-polakow-zamierza-sie-zaszczepic-tak-szybko-jak-to-bedzie-mozliwe/80025 (accessed December 28, 2020).
Republic Service. Vaccination against COVID-19 https://www.gov.pl/web/szczepimysie/dementujemy-nieprawdziwe-informacje (accessed December 28, 2020).
Ahorsu DK, Lin CY, Imani V, et al. The Fear of COVID-19 Scale: development and initial validation. Int. J. Ment. Heal. Ad-dict. 2020;1-9. doi: 10.1007/s11469-020-00270-8.
Pisula E, Nowakowska I. FCV-19S Coronavirus Anxiety Scale https://www.researchgate.net/publication/344690639_Skala_Leku_przed_Koronawirusem_FCV-19S_Ahorsu_i_in_2020_-_polskie_tlumaczenie (accessed December 28, 2020). doi: 10.17605/OSF.IO/39JR8.
Marchewka AK, Majewska A, Mlynarczyk G. The activities of the antivaccine movement, the role of mass media, and the influence of religious views on attitudes toward immunization. Post. Microbiol. 2015;54, 2, 95-102.
Global Attitudes on a COVID-19 Vaccine, Ipsos survey for the World Economic Forum, Conducted on Global Advisor (July 24 - August 7, 2020) https://www.ipsos.com/sites/default/files/ct/news/documents/2020-09/global-attitudes-on-a-covid-19-vaccine-ipsos-survey-for-wef-2020.pdf (accessed December 28, 2020).
Rajkumar RP. COVID-19 and mental health: a review of the existing literature. Asian J. Psychiatry. 2020;52:102066. doi: 10.1016/j.ajp.2020.102066.
Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395,912-920. doi: 10.1016/S0140-6736(20)30460-8.
Alyami M, Henning M, Krägeloh CU, et al. Psychometric evaluation of the Arabic version of the Fear of COVID-19 Scale. Int. J. Ment. Heal. Addict. 2020;1-14. doi: 10.1007/s11469-020-00316-x.
Sakib N, Bhuiyan AKMI, Hossain S, et al. Psychometric validation of the Bangla Fear of COVID-19 Scale: confirmatory fac-tor analysis and rasch analysis. Int. J. Ment. Heal. Addict. 2020;1-12. doi: 10.1007/s11469-020-00289-x.
Soraci P, Ferrari A, Abbiati FA, et al. Validation and psychometric evaluation of the Italian version of the Fear of COVID-19 Scale. Int. J. Ment. Heal. Addict. 2020;1-10. doi: 10.1007/s11469-020-00277-1.
Satici B, Gocet-Tekin E, Deniz ME, et al. Adaptation of the Fear of COVID-19 Scale: its association with psychological dis-tress and life satisfaction in Turkey. Int. J. Ment. Heal. Addict. 2020;1-9. doi: 10.1007/s11469-020-00294-0.
Reznik A, Gritsenko V, Konstantinov V, et al. COVID-19 fear in Eastern Europe: validation of the Fear of COVID-19 Scale. Int. J. Ment. Heal. Addict. 2020;1-6. doi: 10.1007/s11469-020-00283-3.
Tzur Bitan D, Grossman-Giron A, Bloch Y, et al. Fear of COVID-19 Scale: psychometric characteristics, reliability and valid-ity in the Israeli population. Psychiatry Res. 2020;289:113100. doi: 10.1016/j.psychres.2020.113100.
Huarcaya-Victoria J, Villarreal-Zegarra D, Podestà A, et al. Psychometric properties of a Spanish version of the Fear of COVID-19 Scale in general population of Lima, Peru. Int. J. Ment. Heal. Addict. 2020;1-14. doi: 10.1007/s11469-020-00354-5.
Barrios I, Ríos-González C, O'Higgins M, et al. Psychometric properties of the Spanish version of the Fear of COVID-19 Scale (FCV-19S). Int. J. Ment. Heal. Addict. 2020;1-14. doi: 10.21203/RS.3.RS-33345/V1.
Folegatti PM, Ewer KJ, Parvinder KA, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet 2020;396 (10249):467-78.
Tapia MD, Sow SO, Ndiaye BP, et al. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2020;20(6): 719-30.
Coughlan L, Sridhar S, Payne R, et al. Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults. EBioMedicine. 2018;29: 146-54.
Wilkie, M, Satti I, Minhinnicket A, et al. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculo-sis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults. Vaccine. 2020;38(4): 779-89.
Sekine, T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. BioRxiv. 2020. preprint doi: https://doi.org/10.1101/2020.06.29.174888.
Roush SW, Murphy TV, Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mor-tality for vaccine-preventable diseases in the United States. JAMA. 2007;298, 2155-2163.
Mameli C, Cocchi I, Fumagalli M, et al. Influenza Vaccination: Effectiveness, Indications, and Limits in the Pediatric Popu-lation. Front. Pediatr. 2019 https://doi.org/10.3389/fped.2019.00317.
Gawlik K, Woś H, Waksmańska W, et al. Parents' opinions on childhood immunization. General Medicine and Health Sci-ences. 2014;20(4) 360-364.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Mateusz Grajek, Karolina Krupa-Kotara, Karolina Sobczyk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 324
Number of citations: 0
